Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
https://www.channel4.com/news/many-millions-could-be-vaccinated-by-end-of-january-says-oxford-professor
less confident about it working on the SA strain from about 7min 40 secs
Times Radio
1.52K subscribers
Sir John Bell, Regius Professor of Medicine at Oxford University, has warned that the South African variant of COVID is more worrying than the Kent one "by some margin" and that he believes "it's here".
Speaking to Tom Newton-Dunn on Times Radio's G&T programme, he added that there was a "question mark" over whether the vaccine would be effective against the South African strain - but that, if it wasn't, developing a new one might take "a month or six weeks".
He was optimistic on the deployment of the AstraZeneca vaccine, saying that if AstraZeneca geared up production "you could administer 5 million a week if you want to... you don't have to be a doctor, you could administer the bloody thing. It's not complicated to stick a needle in someone's arm. So you just need a doctor there to sign the prescription".
He further added that he understood the UK had "530,000 doses sitting on the shelf as of yesterday, and there's another 450,000 arriving on Monday, so there's a million doses ready to go" of the Oxford/AstraZeneca vaccine.
A little bit of exposure by analysts will do no harm Chelsea. Good trial results should lift Scancell on to the radar of more investors.
Promising science and perhaps a Nasdaq listing could do wonderful things. Look at Beam for example, $15.38 in April, now $95. I am not an investor btw. Heard of them via a deal with Oxford Biomedica.
https://beamtx.com/
`((,(Dieter 'Hovekamp)))
@dhovekamp42
·
19h
$SCLP next gen #COVID19 vaccine trial ahead just to not forget about cancer
@scancellpharma
LSX World Congress 2020 Presentations - #Scancell company update presentation
cc $BNTX
https://youtu.be/TgJXxf3a66M via
https://twitter.com/dhovekamp42/status/1343557005856878596?s=20
I think Burble mentioned Oxford Biomedica re possible manufacturing. This is an interesting article on what goes into vaccine development
https://www.theguardian.com/artanddesign/2020/dec/21/inside-oxfords-coronavirus-vaccine-development
Is there a possibility that the Scancell vaccine could make other Flu/ coronavirus vaccines redundant?
(potential to be effective against any variant or new strain of coronavirus in addition to the current COVID-19 strain.)
providing protection against other coronaviruses due to the N-protein being well conserved across strains.
SN14 is a second generation vaccine which offers several potential advantages over currently approved and late-stage COVID-19 vaccines:
· Not only does SN14 target the S protein to induce VNAbs that prevent the COVID-19 virus from entering cells but also induces strong T cell responses to both the S and N proteins to destroy virally-infected cells and prevent further viral replication.
· As the N protein is well-conserved between coronaviruses, the SN14 vaccine has the potential to be effective against any variant or new strain of coronavirus in addition to the current COVID-19 strain.
· Use of the AvidiMab™ technology increases the potency of the T cell response which, in turn, should lead to long-term protection and immunological memory.
· DNA vaccines are exceptionally stable, do not require ultra-low temperature storage and are manufactured using relatively simple processes.
GSK will have exclusive rights to develop and commercialize SRF813, a novel antibody targeting PVRIG
$85 million upfront payment. In addition, Surface Oncology may receive up to an additional $730 million in future milestone payments, as well as be eligible to receive tiered royalties on global net sales.
HTTps://www.globenewswire.com/news-release/2020/12/17/2146825/0/en/Surface-Oncology-Announces-Exclusive-License-Agreement-with-GSK-for-Novel-Immunotherapy-Program.html#.X9tYvFgqpuU.twitter
John Carroll
@JohnCendpts·
19m
What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on
https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/
VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1
Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion in cash,
https://www.evaluate.com/vantage/articles/news/snippets/velosbio-takes-different-approach-ror1
https://www.businesswire.com/news/home/20201105005543/en/Merck-to-Acquire-VelosBio#.X6Pj0S51Klk.twitter
Crumbs, perhaps you can enlighten me as I am not familiar with Redx. As I understand it;
Yesod's made a cash offer of 15 pence per common share. Rejected over concerns that it undervalued the company and its assets.
But the announcement was followed by another release in which Moulton Goodies Ltd., Redx's largest shareholder, agreed to sell its holdings in the U.K.-based drugmaker — 74,998,896 shares representing 39.5% of the company — to Redmile Group for 15.5 pence apiece.
Redmile made an initial investment in Redx earlier in March, and with the acquisition of Moulton's shares, would end up owning approximately 45.5% of Redx Pharma. As a result, and under U.K. regulation, Redmile is now required to make an offer to buy the rest of the company.
Redmile is offering 15.5 pence apiece for every stock it does not own — above Yesod's latest cash offer of 15 pence per common share, and the offer is backed by the Redx board. The offer values the entire issued and to be issued share capital of Redx at approximately £29.5 million.